KalVista Pharmaceuticals Inc logo

KALV

KalVista Pharmaceuticals Inc

$15.05

Earnings Summary

Revenue
$0Mn
Net Profits
$-24.11Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

KalVista Pharmaceuticals Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2022. On a quarterly growth basis, KalVista Pharmaceuticals Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

KalVista Pharmaceuticals Inc’s net profit fell -61.23% since last year same period to $-24.11Mn in the Q2 2022. On a quarterly growth basis, KalVista Pharmaceuticals Inc has generated -7.33% fall in its net profits since last 3-months.

Net Profit Margins:

KalVista Pharmaceuticals Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2022. On a quarterly growth basis, KalVista Pharmaceuticals Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the KalVista Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-1.03
EPS Estimate Current Year
-1.03

Highlights

EPS Estimate Current Quarter:

KalVista Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -1.03 - a 5.5% jump from last quarter’s estimates.

EPS Estimate Current Year:

KalVista Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -1.03.

Key Ratios

Key ratios of the KalVista Pharmaceuticals Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.98

Highlights

Earning Per Share (EPS):

KalVista Pharmaceuticals Inc’s earning per share (EPS) fell -50.77% since last year same period to -0.98 in the Q2 2022. This indicates that the KalVista Pharmaceuticals Inc has generated -50.77% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-07-07
-1.09
-0.98
10.09%
2022-03-10
-0.93
-0.92
1.08%

Company Information

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021, demonstrating statistical and clinical significance across all endpoints. KVD824 is in development for prophylactic treatment of HAE with a Phase 2 clinical trial expected to initiate in the second quarter of 2021. In addition, KalVista's oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.

Organisation
KalVista Pharmaceuticals Inc
Headquarters
Cambridge, Massachusetts, US
Employees
56
Industry
Health Technology
CEO
Thomas Crockett